Literature DB >> 15865048

Non-invasive imaging of a transgenic mouse model using a prostate-specific two-step transcriptional amplification strategy.

M Iyer1, F B Salazar, X Lewis, L Zhang, L Wu, M Carey, S S Gambhir.   

Abstract

Non-invasive assessment of transgenic animals using bioluminescence imaging offers a rapid means of evaluating disease progression in animal models of disease. One of the challenges in the field is to develop models with robust expression to image repetitively live intact animals through solid tissues. The prostate-specific antigen (PSA) promoter is an attractive model for studying gene regulation due to its hormonal response and tissue-specificity permitting us to measure signaling events that occur within the native tissues. The use of the GAL4-VP16 activator offers a powerful means to augment gene expression levels driven by a weak promoter. We have used a two-step transcriptional amplification (TSTA) system to develop a transgenic mouse model to investigate the tissue-specificity and developmental regulation of firefly luciferase (fl) gene expression in living mice using bioluminescence imaging. We employed an enhanced prostate-specific promoter to drive the yeast transcriptional activator, GAL4-VP16 (effector). The reporter construct carries five Gal4 binding sites upstream of the fl gene. We generated a transgenic mouse model using a single vector carrying the effector and reporter constructs. The transgenic mice show prostate-specific expression as early as three weeks of age. The bioluminescence signal in the prostate is significantly higher than in other organs. We also demonstrate that blocking androgen availability can downregulate the fl expression in the prostate. The transgenic mice display normal physical characteristics and developmental behavior, indicating that the high level of GAL4 driven expression is well tolerated. These findings suggest that the GAL4-VP16 transactivator can be used to amplify reporter gene expression from a relatively weak promoter in a transgenic mouse model. The transgenic TSTA model in conjunction with other transgenic cancer models should also help to detect and track malignancies. The strategies developed will be useful for transgenic research in general by allowing for amplified tissue specific gene expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15865048     DOI: 10.1007/s11248-004-2836-1

Source DB:  PubMed          Journal:  Transgenic Res        ISSN: 0962-8819            Impact factor:   2.788


  27 in total

1.  A 6-kb promoter fragment mimics in transgenic mice the prostate-specific and androgen-regulated expression of the endogenous prostate-specific antigen gene in humans.

Authors:  K B Cleutjens; H A van der Korput; C C Ehren-van Eekelen; R A Sikes; C Fasciana; L W Chung; J Trapman
Journal:  Mol Endocrinol       Date:  1997-08

2.  Bioluminescent indicators in living mammals.

Authors:  P R Contag; I N Olomu; D K Stevenson; C H Contag
Journal:  Nat Med       Date:  1998-02       Impact factor: 53.440

3.  GAL4-VP16 is an unusually potent transcriptional activator.

Authors:  I Sadowski; J Ma; S Triezenberg; M Ptashne
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

4.  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.

Authors:  C Wei; R A Willis; B R Tilton; R J Looney; E M Lord; R K Barth; J G Frelinger
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

5.  Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice.

Authors:  J C Wu; G Sundaresan; M Iyer; S S Gambhir
Journal:  Mol Ther       Date:  2001-10       Impact factor: 11.454

6.  Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters.

Authors:  M Iyer; L Wu; M Carey; Y Wang; A Smallwood; S S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

7.  Evaluation of GAL4/TATA in vivo. Induction of transgene expression by adenovirally mediated gene codelivery.

Authors:  B Fang; L Ji; M Bouvet; J A Roth
Journal:  J Biol Chem       Date:  1998-02-27       Impact factor: 5.157

8.  Herpes simplex virus transcriptional activator VP16 is detrimental to preimplantation development in mice.

Authors:  Y G Yueh; P J Yaworsky; C Kappen
Journal:  Mol Reprod Dev       Date:  2000-01       Impact factor: 2.609

9.  Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice.

Authors:  Pritha Ray; Anna M Wu; Sanjiv S Gambhir
Journal:  Cancer Res       Date:  2003-03-15       Impact factor: 12.701

10.  The EZC-prostate model: noninvasive prostate imaging in living mice.

Authors:  Xiaoming Xie; Zheng Luo; Kevin M Slawin; David M Spencer
Journal:  Mol Endocrinol       Date:  2003-12-18
View more
  12 in total

1.  Noninvasive bioluminescence imaging in small animals.

Authors:  Kurt R Zinn; Tandra R Chaudhuri; April Adams Szafran; Darrell O'Quinn; Casey Weaver; Kari Dugger; Dale Lamar; Robert A Kesterson; Xiangdong Wang; Stuart J Frank
Journal:  ILAR J       Date:  2008

2.  "Same day" ex-vivo regional gene therapy: a novel strategy to enhance bone repair.

Authors:  Mandeep S Virk; Osamu Sugiyama; Sang H Park; Sanjiv S Gambhir; Douglas J Adams; Hicham Drissi; Jay R Lieberman
Journal:  Mol Ther       Date:  2011-02-22       Impact factor: 11.454

3.  Therapeutic effect of targeted Fas-expressing adenoviruses method combining γδ T cells in a mouse model of human ovarian carcinoma.

Authors:  Dingyuan Zeng; Jiajing Lin; Hongying He; Guangping Tan; Ying Lan; Fuyan Jiang; Shuting Sheng
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

4.  Multimodality Molecular Imaging of Cardiac Cell Transplantation: Part I. Reporter Gene Design, Characterization, and Optical in Vivo Imaging of Bone Marrow Stromal Cells after Myocardial Infarction.

Authors:  Natesh Parashurama; Byeong-Cheol Ahn; Keren Ziv; Ken Ito; Ramasamy Paulmurugan; Jürgen K Willmann; Jaehoon Chung; Fumiaki Ikeno; Julia C Swanson; Denis R Merk; Jennifer K Lyons; David Yerushalmi; Tomohiko Teramoto; Hisanori Kosuge; Catherine N Dao; Pritha Ray; Manishkumar Patel; Ya-Fang Chang; Morteza Mahmoudi; Jeff Eric Cohen; Andrew Brooks Goldstone; Frezghi Habte; Srabani Bhaumik; Shahriar Yaghoubi; Robert C Robbins; Rajesh Dash; Phillip C Yang; Todd J Brinton; Paul G Yock; Michael V McConnell; Sanjiv S Gambhir
Journal:  Radiology       Date:  2016-06-16       Impact factor: 11.105

5.  Detecting cancers through tumor-activatable minicircles that lead to a detectable blood biomarker.

Authors:  John A Ronald; Hui-Yen Chuang; Anca Dragulescu-Andrasi; Sharon S Hori; Sanjiv S Gambhir
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-23       Impact factor: 11.205

6.  Potent, tumor-specific gene expression in an orthotopic hepatoma rat model using a Survivin-targeted, amplifiable adenoviral vector.

Authors:  B-C Ahn; J A Ronald; Y I Kim; R Katzenberg; A Singh; R Paulmurugan; S Ray; L V Hofmann; S S Gambhir
Journal:  Gene Ther       Date:  2011-02-10       Impact factor: 5.250

Review 7.  Genetically engineered mouse models of prostate cancer.

Authors:  Maxime Parisotto; Daniel Metzger
Journal:  Mol Oncol       Date:  2013-02-14       Impact factor: 6.603

8.  Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide.

Authors:  Nicholas G Nickols; Peter B Dervan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-12       Impact factor: 11.205

9.  Generation of a highly inducible Gal4-->Fluc universal reporter mouse for in vivo bioluminescence imaging.

Authors:  Andrea Pichler; Julie L Prior; Gary D Luker; David Piwnica-Worms
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-08       Impact factor: 11.205

10.  Lentiviral vectors with amplified beta cell-specific gene expression.

Authors:  K L Shaw; E Pais; S Ge; C Hardee; D Skelton; R P Hollis; G M Crooks; D B Kohn
Journal:  Gene Ther       Date:  2009-05-14       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.